Neurocrine Biosciences, Inc. $NBIX Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 214.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,191 shares of the company’s stock after acquiring an additional 10,357 shares during the quarter. SG Americas Securities LLC’s holdings in Neurocrine Biosciences were worth $2,133,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. HB Wealth Management LLC raised its stake in shares of Neurocrine Biosciences by 62.0% during the third quarter. HB Wealth Management LLC now owns 3,570 shares of the company’s stock worth $501,000 after purchasing an additional 1,366 shares during the last quarter. Cerity Partners LLC increased its stake in Neurocrine Biosciences by 76.3% in the 3rd quarter. Cerity Partners LLC now owns 103,626 shares of the company’s stock valued at $14,547,000 after buying an additional 44,852 shares during the period. Robeco Institutional Asset Management B.V. raised its position in Neurocrine Biosciences by 86.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 28,185 shares of the company’s stock worth $3,957,000 after buying an additional 13,087 shares during the last quarter. Earned Wealth Advisors LLC lifted its stake in shares of Neurocrine Biosciences by 53.8% in the 3rd quarter. Earned Wealth Advisors LLC now owns 2,465 shares of the company’s stock worth $346,000 after acquiring an additional 862 shares during the period. Finally, Asset Management One Co. Ltd. boosted its holdings in shares of Neurocrine Biosciences by 0.8% in the third quarter. Asset Management One Co. Ltd. now owns 40,872 shares of the company’s stock valued at $5,738,000 after acquiring an additional 311 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on NBIX shares. UBS Group increased their price target on shares of Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Zacks Research downgraded Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. Mizuho lifted their price target on Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Citigroup upped their price objective on Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Wednesday, October 8th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.10.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $135.33 on Thursday. The business has a 50 day moving average price of $145.58 and a 200 day moving average price of $139.88. The company has a market capitalization of $13.49 billion, a P/E ratio of 32.38, a PEG ratio of 0.64 and a beta of 0.28. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The company had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. During the same quarter in the prior year, the company earned $1.81 earnings per share. Neurocrine Biosciences’s revenue was up 27.8% compared to the same quarter last year. On average, research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 1,190 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total transaction of $184,557.10. Following the completion of the transaction, the director directly owned 6,239 shares in the company, valued at approximately $967,606.51. This trade represents a 16.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director George J. Morrow sold 15,000 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the transaction, the director owned 7,068 shares of the company’s stock, valued at approximately $1,013,339.16. The trade was a 67.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 43,866 shares of company stock worth $6,570,237 in the last 90 days. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.